CDK 4/6 Inhibitors as Single Agent in Advanced Solid TumorsFrancesco Schettini, Lucia Del Mastro, Irene De Santo et al.|Frontiers in Oncology|2018Cited by 205
Mechanisms of lapatinib resistance in HER2-driven breast cancerValentina Damato, Roberto Bianco, Lucia Raimondo et al.|Cancer Treatment Reviews|2015Cited by 162
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-OncologyCarlo G. Tocchetti, Alexander R. Lyon, Teresa López‐Fernández et al.|European Journal of Heart Failure|2024Cited by 64
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational statusLuigi Formisano, Roberto Bianco|Oncotarget|2015Cited by 42
Insight on the Role of Leptin: A Bridge from Obesity to Breast CancerRoberto Buonaiuto, Carmine De Angelis, Fabiana Napolitano et al.|Biomolecules|2022Cited by 23